Ixazomib Plus Lenalidomide and Dexamethasone Well-Tolerated in Newly Diagnosed Multiple Myeloma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, the combination of ixazomib plus lenalidomide and dexamethasone was well tolerated and demonstrated activity in patients with newly diagnosed multiple myeloma.

For the phase 1/2 study, the researchers sought to investigate the safety and effectiveness of ixazomib, a novel oral proteasome inhibitor, with lenalidomide and dexamethasone. Researchers enrolled 15 patients with newly diagnosed multiple myeloma to the phase 1 portion.

Those patients received escalating doses of ixazomib orally on days 1, 8, and 15, plus lenalidomide 25mg on days 1-21 and dexamethasone 40mg on days 1, 8, 15, and 22. Patients received up to 12 28-day cycles, following by treatment with ixazomib alone.

The recommended dose of ixazomib identified in phase 1 for phase 2 was 2.23mg/m2, which was converted to a 4.0mg fixed dose. In phase 2, researchers enrolled 50 participants and they received the same regimen as in phase 1 with ixazomib given at a dose of 4.0mg.

Results showed that grade 3 or higher adverse effects occurred in 63% of patients and five patients discontinued treatment due to adverse effects. Of the 64 response-evaluable patients, 58% (95% CI: 45 - 70) were said to have had a very good partial response or better.

Patterns of Cadiotoxicity Associated With Carfilzomib
Combination of ixazomib plus lenalidomide and dexamethasone was well tolerated.
In a phase 1/2 trial the authors aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in newly diagnosed multiple myeloma.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs